APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies,

Published on Wed, 13 Jan 2021 14:25:29 +0000 and brought to you by nintex array contains value